U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07367282) titled 'Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration' on Jan. 18.
Brief Summary: If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected. If both eyes are eligible, the eye with the worst best-corrected visual acuity (BCVA) at screening will be chosen. However, if the investigator determines that the other ey...